Biosafe Achieves Full Registration in China
EYSINS, Switzerland, April 8, 2014 /PRNewswire/ --
Biosafe is proud to report that it has just received the official registration of its single use disposable kits with the Chinese FDA. Following earlier approval of the Company's Sepax cell processing machine, Biosafe is now primed to launch sales of its products in the People's Republic of China.
Olivier Waridel, CEO of the Biosafe Group commented: "We are the only company in our field which has received CFDA approval for both its equipment and kits. We are now eager to offer our industry-leading products throughout the People's Republic of China, having set up a Shanghai-based subsidiary in 2012 already. We have been in contact with a number of major Chinese companies and institutions, which will now be able to access our state of the art technology. We see tremendous potential both in the cord blood banking and regenerative medicine markets".
Biosafe's Sepax device, used in conjunction with its proprietary single use disposable kits, offers a wide range of applications in cord blood banking and in the rapidly developing regenerative medicine area. It is used in a point of care environment such as cardiovascular and orthopedic, while in biotechnology and pharmaceutical processes it provides a versatile cell processing platform. Biosafe also offers a range of complementary products, such as the recently launched Smart-Max, for the preparation of cellular products.
About the Biosafe Group
Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and São Paulo) and is present in more than 50 countries, either directly or through distributors.
For further information:
SOURCE Biosafe Group